Navigation Links
Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
Date:3/2/2009

REDWOOD CITY, Calif., March 2 /PRNewswire/ -- Pearl Therapeutics, a biopharmaceutical company developing products for the treatment of widely prevalent respiratory diseases, announced today the appointment of Perry Karsen as Chief Executive Officer.

"We are delighted to attract a corporate leader with such an outstanding record of achievement," stated James W. Young, Ph.D., Venture Partner at 5AM Ventures and Executive Chairman of Pearl Therapeutics. "The Pearl team has made exceptional progress on the development of its portfolio of novel products to treat respiratory diseases and we are confident that Perry, with his extensive background and experience, will contribute significantly to the further success of the company."

"I am truly excited to join the seasoned group of professionals at Pearl working to bring new, high quality therapies to patients with serious respiratory diseases," stated Mr. Karsen. "Pearl's line of products will offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing therapeutics to achieve better clinical outcomes."

As Pearl Therapeutics' new Chief Executive Officer, Perry Karsen brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Perry served as Regional President, Asia/Pacific and Head of Worldwide Business Development at Celgene Corporation, and was also a member of the company's Management, Operating, and Product Development Committees. Previously, Perry held the position of Senior Vice President of Business Development at Human Genome Sciences, and prior to that was a General Partner at Pequot Ventures focusing on venture investments in emerging biopharmaceutical and medical device companies. Earlier, he was Vice President, Corporate Development at Bristol-Myers Squibb and Senior Vice President, Marketing at Zimmer, Inc. Perry was a Director in the Business Development department at Genentech, Inc. and Representative Director of Genentech Japan. Perry began his career with Abbott and over the course of eleven years served in roles of increasing responsibility in product development, international business management, domestic and international marketing, and licensing. He has a Masters of Management degree from Northwestern University's Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois, Urbana.

About Pearl Therapeutics, Inc.

Pearl is developing a portfolio of meaningfully differentiated products to treat respiratory diseases including COPD and asthma. Using its proprietary particle technology, formulation expertise, and unparalleled development experience, Pearl is rapidly advancing a pipeline of products that will offer alternatives to patients and healthcare professionals, ones that better meet their needs, and intend to improve disease management and quality of life.

Founded in 2006, Pearl Therapeutics is privately held and backed by Clarus Ventures, New Leaf Ventures and 5AM Ventures.

    Contacts:
    Pearl Therapeutics
    Adrian Smith
    650.305.2605

    For Pearl Therapeutics
    Jennifer Larson
    415.725.2017
    jlarson@labfive.com


'/>"/>
SOURCE Pearl Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pearl Therapeutics Secures $8 Million in Debt Financing
2. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
3. MUSCs Hollings Cancer Center Dedicates Edwin and Barbara Pearlstine Healing Garden Endowed with $1 Million Gift from Edwin S. Pearlstine, Jr.
4. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
5. String of fullerene pearls
6. Pearl Therapeutics Raises $15.5 Million in Private Financing
7. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
8. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
9. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
10. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
11. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... Willoughby, Ohio (PRWEB) , ... May 02, 2016 ... ... website. Designed with its clients in mind, the fresh look and added functionality ... capabilities. , “Recent years have seen a dynamic shift in agriculture – from ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... medical devices used in spinal surgical procedures, today announced the completion of a ... value proposition for current and future customers and partners. Kohlberg & Company, ...
(Date:4/29/2016)... , April 29, 2016 ... the latest update to its industry-leading treatment planning software, ... that Monaco version 5.11 provides ... now attain calculation speeds up to four times faster ... . With the industry,s gold standard Monte ...
(Date:4/28/2016)... NY (PRWEB) , ... April 28, 2016 , ... ... has made significant investments in recruiting top industry experts, and expanding its LATAM ... which provides industry-leading tools for clients to manage their clinical trial projects. , ...
Breaking Biology Technology:
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/18/2016)... --> --> Competitive Landscape Analysis ... Physical infrastructure and Perimeter Surveillance & Detection Systems ... and the continuing migration crisis in the Middle ... led visiongain to publish this unique report, which is crucial ... & security companies in the border security market and the ...
(Date:3/14/2016)... , March 14, 2016 NXTD ) ... mobile commerce market, announces the airing of a new series ... the week of March 21 st .  The commercials will ... its popular Squawk on the Street show. --> ... the growing mobile commerce market, announces the airing of a ...
Breaking Biology News(10 mins):